MA40057A - Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants - Google Patents
Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinantsInfo
- Publication number
- MA40057A MA40057A MA040057A MA40057A MA40057A MA 40057 A MA40057 A MA 40057A MA 040057 A MA040057 A MA 040057A MA 40057 A MA40057 A MA 40057A MA 40057 A MA40057 A MA 40057A
- Authority
- MA
- Morocco
- Prior art keywords
- skin
- therapeutic
- tratment
- abnormal skin
- microorganisms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Abstract
La présente invention concerne des méthodes de traitement ou de prévention d'états cutanés anormaux chez un homme en ayant besoin, comprenant l'administration d'une composition de culture cellulaire qui comporte une culture vivante de bactéries incluant au moins une souche génétiquement modifiée qui produit un polypeptide recombinant pour le traitement thérapeutique dudit état cutané anormal. L'invention concerne également des compositions pharmaceutiques contenant, en tant que principes actifs, des microorganismes génétiquement modifiés exprimant des polypeptides thérapeutiques recombinants pharmacologiquement actifs non vaccinogènes, en vue de traiter ou de prévenir des états cutanés anormaux.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462005558P | 2014-05-30 | 2014-05-30 | |
US201462005652P | 2014-05-30 | 2014-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40057A true MA40057A (fr) | 2015-12-03 |
Family
ID=54699800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040057A MA40057A (fr) | 2014-05-30 | 2015-05-28 | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants |
Country Status (7)
Country | Link |
---|---|
US (2) | US10702558B2 (fr) |
EP (2) | EP3148569B1 (fr) |
JP (2) | JP6810028B2 (fr) |
CA (1) | CA2979079A1 (fr) |
ES (1) | ES2929579T3 (fr) |
MA (1) | MA40057A (fr) |
WO (1) | WO2015184134A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109715179A (zh) | 2016-04-21 | 2019-05-03 | 内科德生物群系公司 | 用于治疗皮肤病症的组合物和方法 |
WO2018232300A1 (fr) * | 2017-06-16 | 2018-12-20 | Azitra Inc | Compositions et procédés pour le traitement du syndrome de netherton avec des micro-organismes recombinants exprimant lekti |
JP7373176B2 (ja) | 2017-08-31 | 2023-11-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 皮膚の酵素活性を制御する分子的細菌療法 |
CN111278447A (zh) * | 2017-09-05 | 2020-06-12 | 阿兹特拉公司 | 用重组微生物治疗炎性皮肤疾病的方法和组合物 |
JP7121969B2 (ja) * | 2018-02-23 | 2022-08-19 | 株式会社北里コーポレーション | 培養液保護用液状物 |
CN112236153A (zh) | 2018-04-05 | 2021-01-15 | 阿兹特拉公司 | 用重组微生物治疗皮肤疾病的方法和组合物 |
AU2019203692A1 (en) * | 2018-08-30 | 2020-03-19 | Johnson & Johnson Consumer Inc. | Topical composition containing glycerin and yeast extract |
WO2020076770A1 (fr) * | 2018-10-08 | 2020-04-16 | Yale University | Liaison et agrégation sélectives de kératine humaine dans la barrière cutanée à l'aide de sous-domaines de filaggrine humaine sd67 et sd150 |
EP3880241A4 (fr) * | 2018-11-16 | 2022-08-17 | Azitra, Inc. | Souches auxotrophes de bactérie staphylococcus |
CZ201975A3 (cs) * | 2019-02-11 | 2020-03-11 | BiomCare s.r.o. | Kombinované několikastupňové mikrobiální přípravky a způsob jejich aplikace |
US20210070823A1 (en) * | 2019-04-05 | 2021-03-11 | Azitra Inc | Methods and compositions for treating atopic dermatitis with recombinant microorganisms |
US20230087622A1 (en) * | 2020-01-29 | 2023-03-23 | The Jackson Laboratory | Bacterial admixtures |
JP2023546925A (ja) * | 2020-10-21 | 2023-11-08 | ザ ジャクソン ラボラトリー | 抗菌バイオセンサー |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0637384B2 (ja) | 1985-09-21 | 1994-05-18 | 株式会社資生堂 | 皮膚化粧料 |
US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
DE4221268C2 (de) | 1992-06-26 | 1997-06-12 | Lancaster Group Ag | Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut |
DE4221255C2 (de) | 1992-06-26 | 1994-09-15 | Lancaster Group Ag | Phospholipide enthaltendes Kosmetikum |
CA2775111C (fr) | 2009-09-25 | 2019-12-31 | Opko Curna, Llc | Traitement de maladies associees a la filaggrine (flg) par modulation de l'expression et de l'activite de flg |
NO2504357T3 (fr) | 2009-11-23 | 2017-12-30 | ||
US20130078275A1 (en) * | 2010-05-25 | 2013-03-28 | The Board Of Trustees Of The University Of Illinois | Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells |
WO2014025938A1 (fr) | 2012-08-07 | 2014-02-13 | TopGeniX, Inc. | Composition topique comprenant des bactéries transformées exprimant un composé d'intérêt |
KR101491240B1 (ko) | 2013-03-15 | 2015-02-11 | 현대자동차주식회사 | 인비저블 슬라이딩 도어 링크 구조 |
-
2015
- 2015-05-28 EP EP15799765.1A patent/EP3148569B1/fr active Active
- 2015-05-28 MA MA040057A patent/MA40057A/fr unknown
- 2015-05-28 EP EP22182996.3A patent/EP4144756A1/fr active Pending
- 2015-05-28 WO PCT/US2015/032972 patent/WO2015184134A1/fr active Application Filing
- 2015-05-28 JP JP2017515014A patent/JP6810028B2/ja active Active
- 2015-05-28 US US15/312,441 patent/US10702558B2/en active Active
- 2015-05-28 ES ES15799765T patent/ES2929579T3/es active Active
- 2015-05-28 CA CA2979079A patent/CA2979079A1/fr active Pending
-
2020
- 2020-06-02 US US16/890,552 patent/US20210379120A1/en active Pending
- 2020-12-10 JP JP2020205127A patent/JP2021038271A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3148569A1 (fr) | 2017-04-05 |
US20180161380A1 (en) | 2018-06-14 |
JP6810028B2 (ja) | 2021-01-06 |
EP4144756A1 (fr) | 2023-03-08 |
EP3148569A4 (fr) | 2017-11-22 |
WO2015184134A1 (fr) | 2015-12-03 |
US10702558B2 (en) | 2020-07-07 |
EP3148569B1 (fr) | 2022-07-06 |
ES2929579T3 (es) | 2022-11-30 |
JP2017518370A (ja) | 2017-07-06 |
US20210379120A1 (en) | 2021-12-09 |
JP2021038271A (ja) | 2021-03-11 |
CA2979079A1 (fr) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
MX2018005588A (es) | Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno. | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
MY189333A (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
WO2011090297A3 (fr) | Cellule souche adulte humaine pouvant exprimer anti-mdm2 et son utilisation | |
MX2014001393A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas. | |
MX2019001633A (es) | Proteina derivada de la seda para el tratamiento de la inflamacion. | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
MX2017005522A (es) | Tratamiento novedoso de la cornea usando laminina. | |
PH12019501439A1 (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
GB2537783A (en) | Methods and compositions used in treating inflammatory and autoimmune diseases | |
MD4763C1 (ro) | Compoziţie farmaceutică | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
MX2016011002A (es) | Tratamiento de angioedema hereditario con inhibidor c1. | |
BR112018069489A2 (pt) | agente indutor da imunidade e métodos para preparar uma célula apresentadora de antígeno, para preparar uma célula t citotóxica e para induzir a imunidade | |
BR112018069468A2 (pt) | agente indutor da imunidade, métodos para preparar uma célula apresentadora de antígeno, para preparar uma célula t citotóxica e para induzir a imunidade |